Clinical Trials for Kidney Disease in the Era of Personalized Medicine.
作者信息
Heerspink Hiddo J L, Kretzler Matthias
机构信息
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Medicine-Nephrology and Computational Medicine and Bioinformatics University of Michigan, Ann Arbor, Michigan.
出版信息
J Am Soc Nephrol. 2024 Aug 1;35(8):1123-1126. doi: 10.1681/ASN.0000000000000412. Epub 2024 May 9.
Abstract
摘要
相似文献
1
Clinical Trials for Kidney Disease in the Era of Personalized Medicine.
J Am Soc Nephrol. 2024 Aug 1;35(8):1123-1126. doi: 10.1681/ASN.0000000000000412. Epub 2024 May 9.
2
Precision Medicine Approaches in Cardiology and Personalized Therapies for Improved Patient Outcomes: A systematic review.
Curr Probl Cardiol. 2024 May;49(5):102470. doi: 10.1016/j.cpcardiol.2024.102470. Epub 2024 Feb 16.
3
Bridging the United States population diversity gaps in clinical research: roadmap to precision health and reducing health disparities.
Per Med. 2025 May 13:1-11. doi: 10.1080/17410541.2025.2504329.
4
Envisioning the Future of Personalized Medicine: Role and Realities of Digital Twins.
J Med Internet Res. 2024 May 13;26:e50204. doi: 10.2196/50204.
5
The Current Evidence and Future Direction of Adjuvant Treatment for Gastric Cancer in the Era of Precision Medicine.
Cancer Res Treat. 2025 Jul;57(3):621-634. doi: 10.4143/crt.2024.1222. Epub 2025 Jan 23.
6
Nephrogenomics, precision medicine and the role of genetic testing in adult kidney disease management.
Nat Rev Nephrol. 2025 Jun 16. doi: 10.1038/s41581-025-00970-1.
7
Integrating the patient voice: patient-centred and equitable clinical risk prediction for kidney health and disease.
Curr Opin Nephrol Hypertens. 2024 Jul 1;33(4):456-463. doi: 10.1097/MNH.0000000000000993. Epub 2024 Apr 24.
8
Genomics in Clinical trials for Breast Cancer.
Brief Funct Genomics. 2024 Jul 19;23(4):325-334. doi: 10.1093/bfgp/elad054.
9
Pharmacogenomics and rare diseases: optimizing drug development and personalized therapeutics.
Pharmacogenomics. 2025 Feb-Mar;26(3-4):121-128. doi: 10.1080/14622416.2025.2490465. Epub 2025 Apr 7.
10
Exploring interdisciplinary perspectives on the implementation of and in Alzheimer's disease: A qualitative study within the ABOARD research project.
J Alzheimers Dis. 2025 May;105(1):120-133. doi: 10.1177/13872877251326166. Epub 2025 Mar 21.
引用本文的文献
1
Enhancing collaboration between academia and industry in kidney disease research.
Nephrol Dial Transplant. 2025 Apr 28;40(5):836-838. doi: 10.1093/ndt/gfae272.
本文引用的文献
1
Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine.
Kidney Int. 2024 Jun;105(6):1263-1278. doi: 10.1016/j.kint.2024.01.012. Epub 2024 Jan 27.
2
Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today.
Kidney Int. 2024 Feb;105(2):218-230. doi: 10.1016/j.kint.2023.11.018.
3
Precision medicine in regulatory decision making: Biomarkers used for patient selection in European Public Assessment Reports from 2018 to 2020.
Clin Transl Sci. 2023 Nov;16(11):2394-2412. doi: 10.1111/cts.13641. Epub 2023 Oct 18.
4
Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes.
Kidney Int. 2023 Oct;104(4):828-839. doi: 10.1016/j.kint.2023.07.007. Epub 2023 Aug 4.
5
An atlas of healthy and injured cell states and niches in the human kidney.
Nature. 2023 Jul;619(7970):585-594. doi: 10.1038/s41586-023-05769-3. Epub 2023 Jul 19.
6
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
JAMA. 2023 Apr 11;329(14):1160-1169. doi: 10.1001/jama.2023.3322.
7
Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.
Diabetes Care. 2023 Mar 1;46(3):593-601. doi: 10.2337/dc22-1699.
8
Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial.
J Am Soc Nephrol. 2021 Nov;32(11):2900-2911. doi: 10.1681/ASN.2021030391. Epub 2021 Sep 22.
9
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
Lancet Diabetes Endocrinol. 2020 Apr;8(4):301-312. doi: 10.1016/S2213-8587(20)30026-7. Epub 2020 Mar 2.
10
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14.
Zotero 插件